Skip to main content
57°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fibrogen Inc CS
(NQ:
FGEN
)
1.160
+0.020 (+1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fibrogen Inc CS
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Couchbase Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 07, 2023
Gainers Mobiquity Technologies, Inc. (NASDAQ: MOBQ) shares gained 124% to $0.3325. Mobiquity Technologies launched ElecAlytics, an AI-Powered analytics suite added to its ElecTech platform for...
Via
Benzinga
FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost
June 07, 2023
The company's lead drug didn't improve upper-limb mobility for some patients with the disease.
Via
Investor's Business Daily
FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal
June 07, 2023
FibroGen Inc (NASDAQ: FGEN) announced topline data from the Phase 3 LELANTOS-1 trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD)
Via
Benzinga
FibroGen's Return on Invested Capital Overview
May 23, 2023
Via
Benzinga
FibroGen's Anemia Candidate Fails In Myelodysplastic Syndrome Study
May 05, 2023
Via
Benzinga
FibroGen Earnings Preview
May 05, 2023
Via
Benzinga
FibroGen's Return On Capital Employed Insights
March 02, 2023
Via
Benzinga
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90
June 06, 2023
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
June 02, 2023
Via
Benzinga
Why did Sarepta Therapeutics Stock Plummet?
March 21, 2023
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Via
MarketBeat
Exposures
Product Safety
Analyst Ratings for FibroGen
February 28, 2023
Via
Benzinga
Earnings Preview For FibroGen
February 24, 2023
Via
Benzinga
B of A Securities Upgrades FibroGen: Here's What You Need To Know
January 05, 2023
Via
Benzinga
Short Volatility Alert: FibroGen, Inc.
August 31, 2022
On Tuesday, shares of FibroGen, Inc. (NASDAQ: FGEN) experienced volatile short activity. After the activity, the stock price went down -4.38% to $12.87. The overall sentiment for FGEN has been...
Via
Benzinga
Earnings Scheduled For February 27, 2023
February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.
Via
Benzinga
Recap: FibroGen Q2 Earnings
August 08, 2022
FibroGen (NASDAQ:FGEN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
FibroGen Shares Gain As Analyst Creates Bullish Pitch On Pulmonary Fibrosis Opportunity
January 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023
January 31, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
January 26, 2023
Via
Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 05, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...
Via
Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
November 08, 2022
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
November 09, 2022
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.
Via
Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
November 08, 2022
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast...
Via
Benzinga
FibroGen Earnings Preview
November 04, 2022
FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report...
Via
Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
September 23, 2022
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.
Via
InvestorPlace
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
August 26, 2022
Via
Benzinga
FibroGen Concludes Dosing In Late-Stage Blood Cell Disorder Study, Sees Top-line Data In H1 2023
August 26, 2022
FibroGen, Inc. (NASDAQ: FGEN) has completed patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent...
Via
Benzinga
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
August 19, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Preview: FibroGen's Earnings
August 05, 2022
FibroGen (NASDAQ:FGEN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that FibroGen will report...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.